Soleno reports Q3 2022 net loss of $6.1M; initiates randomized withdrawal of DCCR study for PWS

SOLENO THERAPEUTICS INC

2022-Q3 EPS reported -$2.60

Cash at Sep 30, 2022: $19.8M; sufficient to fund operations through H1 2023 top-line data.
Net loss Q3 2022: $6.1M ($0.76 per share) vs $8.1M ($1.53) YoY.
R&D expense decreased to $3.8M from $5.0M YoY; G&A down to $2.3M.
Initiated randomized withdrawal period of Study C602 for DCCR in PWS; top-line data expected H1 2023.
FDA acknowledged that data from the study could support NDA submission.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SOLENO THERAPEUTICS INC reported the three and nine months ended September 30, 2022 results: net income Net loss for the three and nine months ended September 30, 2022, was $6.1 million and $18.6 million, or a net loss of $0, EPS a net loss of $0.76 and $2.60 per basic and diluted share.

Period: the three and nine months ended September 30, 2022
Net income: Net loss for the three and nine months ended September 30, 2022, was $6.1 million and $18.6 million, or a net loss of $0
EPS: a net loss of $0.76 and $2.60 per basic and diluted share
Result: reported results

Exact text from the filing

Soleno Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

SOLENO THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001193125-22-281213

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.